COMPANY OVERVIEW

None

---

LOCATION

---

THERAPEUTIC AREAS

---

WEBSITE

None

---

CAREER WEBSITE

None

---

SOCIAL MEDIA

---

INVESTORS

---

PRESS RELEASES

Jan 16, 2018

Aspyrian Therapeutics Inc. announces successful advances in RM-1929 clinical development in recurrent Head and Neck Cancer, including Fast Track designation granted by the FDA, initiation of clinical studies in Japan, and plans to start pivotal studies, which will incorporate the evaluation of anti-cancer immune responses, in early 2018

Jul 19, 2017

Aspyrian Therapeutics, Inc. closes $15.1M as part of a Series B-1 financing to support the advancement of its proprietary precision targeted therapy, RM-1929, to late stage clinical development and the progression of new proprietary immune oncology assets into the clinic.

Mar 10, 2016

Aspyrian Therapeutics Inc. closes a $40M Series B financing to advance the precision targeted cancer therapy, RM-1929, to late stage clinical development in recurrent head and neck cancer and other cancer areas.

Jul 27, 2015

Aspyrian Therapeutics Inc. Closes $4.25M Series A Extension Financing to Support the Execution of Phase 1 Clinical Studies of the Precision Targeted Cancer Therapy, RM-1929, to Treat Late-Stage Recurrent Head and Neck Cancers

Jun 9, 2015

Goodwin Biotechnology and Aspyrian Therapeutics Collaborate on the Successful GMP Manufacturing and IND Submission for a Novel Antibody Drug Conjugate (ADC) Platform

For More Press Releases

---